Welcome to womble perspectives, where we explore a wide range of topics, from the latest legal updates to industry trends to the business of law. Our team of lawyers, professionals and occasional outside guests will take you through the most pressing issues facing businesses today and provide practical and actionable advice to help you navigate the ever changing legal landscape.
With a focus on innovation, collaboration and client service, we are committed to delivering exceptional value to our clients and to the communities we serve. And now our latest episode.
On April 30, 2024, the landscape of the cannabis industry experienced a monumental shift when the US Drug Enforcement Administration announced its decision to reclassify cannabis from a schedule I to schedule III substance under the Controlled Substances act. This move, coming after an 18 month review initiated by the Biden administration, is seen as a significant step towards acknowledging the therapeutic potential of cannabis and easing federal restrictions that have long hampered the industry.
Cannabis has been classified as a schedule I drug for decades, placing it alongside substances deemed to have no currently accepted medical use and a high potential for abuse. This classification has imposed severe limitations on cannabis research, development, and commerce.
The decision to reclassify cannabis to schedule III, home to substances like ketamine and certain anabolic steroids, was influenced by a recommendation from the US Department of Health and Human Services, signaling a shift in governmental standpoint on the plant's potential benefits.
The DEA's announcement marks the beginning of a regulatory process requiring review by the White House Office of Management and Budget and a public comment period before finalizing the rule. If approved, this reclassification could significantly alter the federal government's stance on cannabis, paving the way for increased research and commercial activities.
A schedule III classification implies that a substance has a recognized medical use and a moderate to low potential for physical dependence or high psychological dependence. Transitioning cannabis to this category would reduce regulatory hurdles for research and signal a formal acknowledgement of its medical applications, potentially influencing further FDA approvals.
The reclassification of cannabis would not immediately resolve the longstanding conflict between federal law and state laws where cannabis is legal, either for medicinal or recreational use. However, it represents a critical step towards reconciling these discrepancies. This change would necessitate a review of how cannabis is prescribed and accessed, moving it closer to the way FDA approved drugs are handled for cannabis businesses.
Transitioning to schedule III could alleviate the heavy tax burdens posed by IR's code, section 280 E, which currently prohibits the deduction of regular business expenses due to the federal illegality of cannabis. This change could unlock significant economic potential for the industry, improving operational efficiencies, and fostering growth. The DEA's decision is likely to encourage Congress to consider establishing a new regulatory framework for cannabis, particularly for adult use, mirroring the approach taken with hemp derived CBD products in 2023. This would necessitate creating a novel regulatory pathway that accommodates the unique nature of the cannabis industry.
Legislative initiatives such as the Safer Banking act aim to integrate legal cannabis businesses into the mainstream financial system, offering a glimpse into the possible future of federal cannabis policy. Though its outcome remains uncertain. The act represents a bipartisan effort to support the burgeoning cannabis industry.
The DEA's historic decision to reclassify cannabis opens the door to numerous possibilities for the cannabis industry. While challenges remain, particularly in harmonizing federal and state laws, the move is a clear indicator of the shifting attitudes towards cannabis use and its role within the medical community and beyond.
Thank you for listening to womble perspectives. If you want to learn more about the topics discussed in this episode, please visit the show notes where you can find links to related resources mentioned today.
The show notes also have more information about our attorneys who provided today's insights, including ways to reach out to them. Don't forget to subscribe via your podcast player of choice so that you never miss an episode. Thank you again for listening.